Difluorocarbene radiosynthesis
US-2024383827-A1 · Nov 21, 2024 · US
US9359275B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9359275-B2 |
| Application number | US-201313776144-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 25, 2013 |
| Priority date | Feb 23, 2012 |
| Publication date | Jun 7, 2016 |
| Grant date | Jun 7, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are pure and isolated natural products and analogs thereof of Formula (I), (II), (III), and (IV), pharmaceutical compositions thereof, and methods of use, for example, for treating a bacterial infection. Further provided are methods useful in identifying an inhibitor of bacterial sugar fermentation in a bacterial strain, such as a compound (inhibitor) of Formula (I), (II), (III), or (IV): or a pharmaceutically acceptable salt thereof.
Opening claim text (preview).
What is claimed is: 1. A method of treating a bacterial infection in a subject comprising administering an effective amount of a compound of Formula (I-b): or pharmaceutically acceptable salt thereof, to the subject; wherein: each occurrence of R A , R B , and R C is hydrogen; R 3 is unsubstituted C 2 -C 10 alkyl, wherein the bacterial infection is an Escherichia coli, Pseudomonas aeruginosa, Vibrio cholerae , methicillin-resistant Staphylococcus aureus , or Mycobacterium tuberculosis infection. 2. The method of claim 1 wherein R 3 is unsubstituted C 2 -C 6 alkyl. 3. The method of claim 1 wherein the compound is of Formula (I-c): or a pharmaceutically acceptable salt thereof. 4. The method of claim 1 wherein the compound is: or a pharmaceutically acceptable salt thereof. 5. The method of claim 1 , wherein the bacterial infection is a methicillin-resistant Staphylococcus aureus infection. 6. The method of claim 1 , wherein the bacterial infection is a Mycobacterium tuberculosis infection. 7. The method of claim 1 , wherein the bacterial infection is a methicillin-resistant Staphylococcus aureus infection or a Mycobacterium tuberculosis infection.
Oxygen atoms · CPC title
having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin · CPC title
Alkylated hydroxy benzenes containing also acyclically bound hydroxy groups, e.g. saligenol · CPC title
not condensed with another ring · CPC title
containing —CHO or non—quinoid keto groups · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.